Related Experiment Video
Updated: Jul 29, 2025

In Vivo Mouse Model of Spinal Implant Infection
Published on: June 23, 2020
Concentrations of Co-Administered Meropenem and Vancomycin in Spinal Tissues Relevant for the Treatment of Pyogenic
Josefine Slater1,2,3, Maiken Stilling1,2,3, Pelle Hanberg1,3
1Department of Orthopaedic Surgery, Aarhus University Hospital, 8200 Aarhus, Denmark.
Abstract:
Co-administration of meropenem and vancomycin has been suggested as a systemic empirical antibiotic treatment of pyogenic spondylodiscitis. The aim of this study was, in an experimental porcine model, to evaluate the percentage of an 8-h dosing interval of co-administered meropenem and vancomycin concentrations above the relevant minimal inhibitory concentrations (MICs) (%T>MIC) in spinal tissues using microdialysis. Eight female pigs (Danish Landrace breed, weight 78-82 kg) received a single-dose bolus infusion of 1000 mg of meropenem and 1000 mg vancomycin simultaneously before microdialysis sampling. Microdialysis catheters were applied in the third cervical (C3) vertebral cancellous bone, the C3-C4 intervertebral disc, paravertebral muscle, and adjacent subcutaneous tissue. Plasma samples were obtained for reference. The main finding was that for both drugs, the %T>MICs were highly reliant on the applied MIC target, but were heterogeneous across all targeted tissues, ranging from 25-90% for meropenem, and 10-100% for vancomycin. For both MIC targets, the highest %T>MIC was demonstrated in plasma, and the lowest %T>MIC was demonstrated in the vertebral cancellous bone for meropenem, and in the intervertebral disc for vancomycin. When indicated, our findings may suggest a more aggressive dosing approach of both meropenem and vancomycin to increase the spinal tissue concentrations to treat the full spectrum of potentially encountered bacteria in a spondylodiscitis treatment setting.
Insights
Co-administering meropenem and vancomycin for pyogenic spondylodiscitis showed varied spinal tissue concentrations. Dosing may need adjustment to ensure adequate antibiotic levels against bacteria in bone and disc infections.
Area of Science:
- Pharmacology
- Infectious Diseases
- Surgical Infections
Background:
- Pyogenic spondylodiscitis treatment often involves empirical antibiotics like meropenem and vancomycin.
- Systemic co-administration aims to achieve therapeutic drug concentrations in spinal tissues.
- Evaluating drug penetration into spinal tissues is crucial for optimizing treatment efficacy.
Purpose of the Study:
- To assess the time above minimal inhibitory concentration (%T>MIC) for meropenem and vancomycin in porcine spinal tissues.
- To compare drug concentrations in vertebral bone, intervertebral discs, muscle, and plasma.
- To determine the influence of MIC targets on %T>MIC in different spinal compartments.
Main Methods:
- Utilized an experimental porcine model to simulate pyogenic spondylodiscitis treatment.
- Administered a single dose of meropenem (1000 mg) and vancomycin (1000 mg) intravenously.
- Employed microdialysis in cervical vertebral bone, intervertebral disc, paravertebral muscle, and subcutaneous tissue for drug concentration analysis.
- Collected plasma samples for reference pharmacokinetic data.
Main Results:
- %T>MIC values were highly dependent on the selected minimal inhibitory concentration (MIC) target for both antibiotics.
- Significant heterogeneity in %T>MIC was observed across all investigated spinal tissues.
- Meropenem showed lower %T>MIC in vertebral bone, while vancomycin had lower %T>MIC in the intervertebral disc.
- Plasma exhibited the highest %T>MIC for both drugs, indicating better systemic than local tissue penetration.
Conclusions:
- Current dosing of meropenem and vancomycin may not consistently achieve target %T>MIC in spinal tissues for spondylodiscitis.
- Heterogeneous drug distribution necessitates consideration of MIC variability and tissue penetration.
- A more aggressive dosing strategy for meropenem and vancomycin might be required to ensure effective treatment of spinal infections.
Related Concept Videos
Acute Pyelonephritis II: Diagnostic Studies and Management
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Local Anesthetics: Clinical Application as Spinal Anesthesia
Acute Pyelonephritis I: Introduction

